Renaissance Technologies’s Crinetics Pharmaceuticals CRNX Stock Holding History

Renaissance Technologies’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-11,700	Closed	-$416K	–	3759
2023 Q4	$416K	Sell	11,700 -152,000	-93%	-$4.66M	﹤0.01%	2853
2023 Q3	$4.87M	Buy	+163,700	New	+$3.37M	0.01%	1326
2023 Q1	–	Sell	-63,100	Closed	-$1.16M	–	4030
2022 Q4	$1.16M	Buy	+63,100	New	+$1.11M	﹤0.01%	2444
2022 Q3	–	Sell	-86,400	Closed	-$1.61M	–	4071
2022 Q2	$1.61M	Buy	+86,400	New	+$1.72M	﹤0.01%	2352
2021 Q1	–	Sell	-25,500	Closed	-$360K	–	3367
2020 Q4	$360K	Buy	+25,500	New	+$355K	﹤0.01%	2969
2020 Q3	–	Sell	-35,600	Closed	-$624K	–	3417
2020 Q2	$624K	Buy	+35,600	New	+$607K	﹤0.01%	2786

Other funds holding CRNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies's CRNX Position: Q1 2024 in Review

Renaissance Technologies sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2024, closing a stake of 11,700 shares — an estimated $416K sold.

Renaissance Technologies first reported a position in CRNX in Q2 2020 and held it in 6 quarters. The position peaked at $4.87M in Q3 2023. 203 funds tracked by Wall St. Rank hold CRNX as of Q1 2024.

Renaissance Technologies reported no remaining Crinetics Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Renaissance Technologies sold 11,700 Crinetics Pharmaceuticals shares in Q1 2024, an estimated $416K.
Renaissance Technologies first reported a position in Crinetics Pharmaceuticals in Q2 2020 and held it in 6 quarters.
Renaissance Technologies's Crinetics Pharmaceuticals position peaked at $4.87M in Q3 2023.
203 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2024.

Based on Renaissance Technologies's 13F filing for Q1 2024, filed 13 May 2024.